Atorvastatin and Fluvastatin Are Associated with Dose-dependent Reductions in Cirrhosis and Hepatocellular Carcinoma, Among Patients with Hepatitis C Virus: Results from ERCHIVES

Overview

Journal Hepatology

Specialty Gastroenterology

Date 2016 Feb 19

PMID 26891205

Citations 84

Authors

Tracey G Simon

Hector Bonilla

Peng Yan

Raymond T Chung

Adeel A Butt

Affiliations

Soon will be listed here.

Abstract

Unlabelled: Statins are associated with delayed fibrosis progression and a reduced risk of hepatocellular carcinoma (HCC) in chronic hepatitis C virus (HCV). Limited data exist regarding the most effective type and dose of statin in this population. We sought to determine the impact of statin type and dose upon fibrosis progression and HCC in patients with HCV. Using the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES) database, we identified all subjects initiated on HCV antibody (anti-HCV) therapy from 2001 to 2014, and all incident cases of cirrhosis and HCC. Statin use was measured using cumulative defined daily dose (cDDD). Multivariable Cox's proportional hazard regression models were used to examine the relationship between statin use and development of cirrhosis and HCC. Among 9,135 eligible subjects, 1,649 developed cirrhosis and 239 developed incident HCC. Statin use was associated with a 44% reduction in development of cirrhosis (adjusted hazard ratio [HR]: 0.6; 95% confidence interval [CI]: 0.53, 0.68). The adjusted HRs (95% CI) of fibrosis progression with statin cDDD 28-89, 89-180, and >180 were 0.74 (0.59, 0.93), 0.71 (0.59, 0.88), and 0.6 (0.53, 0.68), respectively. Mean change in FIB-4 score with atorvastatin (n = 944) and fluvastatin (n = 34) was -0.17 and -0.13, respectively (P = 0.04), after adjustment for baseline FIB-4 score and established predictors of cirrhosis. Statin use was also associated with a 49% reduction in incident HCC (adjusted HR: 0.51; 95% CI: 0.36, 0.72). A similar dose-response relationship was observed.

Conclusion: In patients with chronic HCV, statin use was associated with a dose-dependent reduction in incident cirrhosis and HCC. Atorvastatin and fluvastatin were associated with the most significant antifibrotic effects, compared with other statins. (Hepatology 2016;64:47-57).

Citing Articles

SATB1 in cancer progression and metastasis: mechanisms and therapeutic potential.

Bai J, Yang G, Yu Q, Chi Q, Zeng X, Qi W Front Oncol. 2025; 15:1535929.

PMID: 40071088 PMC: 11893431. DOI: 10.3389/fonc.2025.1535929.

Association of Statin, Metformin, and Aspirin Use With Hepatocellular Carcinoma in the Research Program.

Almazan E, Chung R Gastro Hep Adv. 2025; 4(1):100535.

PMID: 39758847 PMC: 11699276. DOI: 10.1016/j.gastha.2024.08.014.

Statins decrease the risk of hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis.

Tarar Z, Farooq U, Inayat F, Basida S, Ibrahim F, Gandhi M World J Exp Med. 2024; 14(4):98543.

PMID: 39713070 PMC: 11551700. DOI: 10.5493/wjem.v14.i4.98543.

Current and emerging strategies for the prevention of hepatocellular carcinoma.

Yeo Y, Abdelmalek M, Khan S, Moylan C, Rodriquez L, Villanueva A Nat Rev Gastroenterol Hepatol. 2024; 22(3):173-190.

PMID: 39653784 DOI: 10.1038/s41575-024-01021-z.

Mechanisms and implications of recompensation in cirrhosis.

Piano S, Reiberger T, Bosch J JHEP Rep. 2024; 6(12):101233.

PMID: 39640222 PMC: 11617229. DOI: 10.1016/j.jhepr.2024.101233.

References

van der Meer A, Veldt B, Feld J, Wedemeyer H, Dufour J, Lammert F . Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012; 308(24):2584-93. DOI: 10.1001/jama.2012.144878. View

Chong L, Hsu Y, Lee T, Lin Y, Chiu Y, Yang K . Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells. BMC Gastroenterol. 2015; 15:22. PMC: 4336504. DOI: 10.1186/s12876-015-0248-8. View

Skogastierna C, Johansson M, Parini P, Eriksson M, Eriksson L, Ekstrom L . Statins inhibit expression of thioredoxin reductase 1 in rat and human liver and reduce tumour development. Biochem Biophys Res Commun. 2012; 417(3):1046-51. DOI: 10.1016/j.bbrc.2011.12.091. View

Kisseleva T, Brenner D . Anti-fibrogenic strategies and the regression of fibrosis. Best Pract Res Clin Gastroenterol. 2011; 25(2):305-17. PMC: 3086317. DOI: 10.1016/j.bpg.2011.02.011. View

Kapadia S, Chisari F . Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci U S A. 2005; 102(7):2561-6. PMC: 549027. DOI: 10.1073/pnas.0409834102. View

Welzel T, Graubard B, Zeuzem S, El-Serag H, Davila J, McGlynn K . Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology. 2011; 54(2):463-71. PMC: 4141525. DOI: 10.1002/hep.24397. View

Thomas D, Seeff L . Natural history of hepatitis C. Clin Liver Dis. 2005; 9(3):383-98, vi. DOI: 10.1016/j.cld.2005.05.003. View

Konishi I, Hiasa Y, Shigematsu S, Hirooka M, Furukawa S, Abe M . Diabetes pattern on the 75 g oral glucose tolerance test is a risk factor for hepatocellular carcinoma in patients with hepatitis C virus. Liver Int. 2009; 29(8):1194-201. DOI: 10.1111/j.1478-3231.2009.02043.x. View

Siegel A, Zhu A . Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer. 2009; 115(24):5651-61. PMC: 3397779. DOI: 10.1002/cncr.24687. View

10.

Bonovas S, Filioussi K, Tsavaris N, Sitaras N . Statins and cancer risk: a literature-based meta-analysis and meta-regression analysis of 35 randomized controlled trials. J Clin Oncol. 2006; 24(30):4808-17. DOI: 10.1200/JCO.2006.06.3560. View

11.

Freed-Pastor W, Prives C . Mutant p53: one name, many proteins. Genes Dev. 2012; 26(12):1268-86. PMC: 3387655. DOI: 10.1101/gad.190678.112. View

12.

Rao S, Porter D, Chen X, Herliczek T, Lowe M, Keyomarsi K . Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci U S A. 1999; 96(14):7797-802. PMC: 22141. DOI: 10.1073/pnas.96.14.7797. View

13.

Relja B, Meder F, Wilhelm K, Henrich D, Marzi I, Lehnert M . Simvastatin inhibits cell growth and induces apoptosis and G0/G1 cell cycle arrest in hepatic cancer cells. Int J Mol Med. 2010; 26(5):735-41. DOI: 10.3892/ijmm_00000520. View

14.

Farwell W, Scranton R, Lawler E, Lew R, Brophy M, Fiore L . The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst. 2008; 100(2):134-9. DOI: 10.1093/jnci/djm286. View

15.

Poynter J, Gruber S, Higgins P, Almog R, Bonner J, Rennert H . Statins and the risk of colorectal cancer. N Engl J Med. 2005; 352(21):2184-92. DOI: 10.1056/NEJMoa043792. View

16.

Miyaki T, Nojiri S, Shinkai N, Kusakabe A, Matsuura K, Iio E . Pitavastatin inhibits hepatic steatosis and fibrosis in non-alcoholic steatohepatitis model rats. Hepatol Res. 2011; 41(4):375-85. DOI: 10.1111/j.1872-034X.2010.00769.x. View

17.

Singh S, Paul Singh P, Singh A, Murad M, Sanchez W . Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology. 2012; 144(2):323-332. DOI: 10.1053/j.gastro.2012.10.005. View

18.

Relja B, Meder F, Wang M, Blaheta R, Henrich D, Marzi I . Simvastatin modulates the adhesion and growth of hepatocellular carcinoma cells via decrease of integrin expression and ROCK. Int J Oncol. 2011; 38(3):879-85. DOI: 10.3892/ijo.2010.892. View

19.

Clendening J, Penn L . Targeting tumor cell metabolism with statins. Oncogene. 2012; 31(48):4967-78. DOI: 10.1038/onc.2012.6. View

20.

Wu J, Wong W, Khosravi F, Minden M, Penn L . Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res. 2004; 64(18):6461-8. DOI: 10.1158/0008-5472.CAN-04-0866. View